FDA warned Guangxi Yulin Pharmaceutical Group that its OTC drugs lacked release testing and had data integrity failures.
What happened
FDA inspected the drug manufacturing facility in Yulin, Guangxi, China, from March 17 to 21, 2025. FDA found that the firm released drug products without testing identity and strength of active ingredients, did not show its test methods were suitable or equivalent to United States Pharmacopeia methods, lacked adequate stability data, and lacked controls to prevent deletion or alteration of lab data. FDA said the firm's response was inadequate and that some problems repeated from a 2016 inspection.
What FDA found
Failed to test each batch for identity and strength of active ingredients before release.
21 CFR 211.165(a)Failed to establish scientifically sound test methods and specifications, including showing equivalence to United States Pharmacopeia methods.
21 CFR 211.160(b)Failed to have adequate stability data and a stability program to support the labeled shelf life.
21 CFR 211.166(a)Lab computer systems lacked records of who changed data, and analysts could alter or delete files.
21 CFR 211.68(b)
What FDA wants
Respond in writing within 15 working days describing what you have done to correct violations and prevent recurrence. FDA also recommends engaging a qualified CGMP consultant to perform a six-system audit before seeking resolution of compliance status.
Who should pay attention
- U.S. buyers and distributors of OTC drugs from this firm
- companies relying on Chinese Pharmacopeia methods for U.S. products
- quality teams managing lab data integrity and supplier audits
This is a summary. Read the original letter on fda.gov.